keyword
MENU ▼
Read by QxMD icon Read
search

Tnbc

keyword
https://www.readbyqxmd.com/read/28338932/ursolic-acid-derivative-fzu-03-010-inhibits-stat3-and-induces-cell-cycle-arrest-and-apoptosis-in-renal-and-breast-cancer-cells
#1
Wei Li, Hongxiu Zhang, Mingxiu Nie, Yanlei Tian, Xu Chen, Ceshi Chen, Haijun Chen, Rong Liu
Advanced renal cell carcinoma and triple negative breast cancer (TNBC) are malignancies without effective therapeutics currently. Ursolic acid (UA) has been previously reported to have anti-cancer effects in multiple solid tumors. In order to develop more potent anti-cancer reagents, FZU-03,010 based on the chemical structure of UA were synthesized. The results demonstrated that, compared with UA, FZU-03,010 could suppress renal cancer cell 786-0 and TNBC cell HCC1806 cell viability more potently.  Furthermore, FZU-03,010 could induce G1 cell cycle arrest and cell apoptosis more efficiently than UA...
March 2, 2017: Acta Biochimica et Biophysica Sinica
https://www.readbyqxmd.com/read/28337281/c-myc-induced-upregulation-of-lncrna-snhg12-regulates-cell-proliferation-apoptosis-and-migration-in-triple-negative-breast-cancer
#2
Ouchen Wang, Fan Yang, Yehuan Liu, Lin Lv, Ruimin Ma, Chuanzhi Chen, Jiao Wang, Qiufan Tan, Yue Cheng, Erjie Xia, Yizuo Chen, Xiaohua Zhang
Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, with a significantly higher recurrence and mortality rate. There is an urgent need to uncover the mechanism underlying TNBC and establish therapeutic targets. Long non-coding RNAs (lncRNAs) are involved in a series of biological functions and provide novel insights into the molecular mechanism of cancer. Based on their expression specificity and large number, lncRNAs are likely to serve as the basis for clinical applications in oncology...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28333150/kaiso-depletion-attenuates-the-growth-and-survival-of-triple-negative-breast-cancer-cells
#3
Blessing I Bassey-Archibong, Lyndsay G A Rayner, Shawn M Hercules, Craig W Aarts, Anna Dvorkin-Gheva, Jonathan L Bramson, John A Hassell, Juliet M Daniel
Triple negative breast cancers (TNBC) are highly aggressive and lack specific targeted therapies. Recent studies have reported high expression of the transcription factor Kaiso in triple negative tumors, and this correlates with their increased aggressiveness. However, little is known about the clinical relevance of Kaiso in the growth and survival of TNBCs. Herein, we report that Kaiso depletion attenuates TNBC cell proliferation, and delays tumor onset in mice xenografted with the aggressive MDA-231 breast tumor cells...
March 23, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28331788/periodic-mesoporous-organosilica-coated-prussian-blue-for-mr-pa-dual-modal-imaging-guided-photothermal-chemotherapy-of-triple-negative-breast-cancer
#4
Wei Tian, Yunyan Su, Ying Tian, Shouju Wang, Xiaodan Su, Ying Liu, Yunlei Zhang, Yuxia Tang, Qianqian Ni, Wenfei Liu, Meng Dang, Chunyan Wang, Junjie Zhang, Zhaogang Teng, Guangming Lu
Complete eradication of highly aggressive triple negative breast cancer (TNBC) remains a notable challenge today. In this work, an imaging-guided photothermal-chemotherapy strategy for TNBC is developed for the first time based on a periodic mesoporous organosilica (PMO) coated Prussian blue (PB@PMO) nanoplatform. The PB@PMOs have organic-inorganic hybrid frameworks, uniform diameter (125 nm), high surface area (866 m(2) g(-1)), large pore size (3.2 nm), excellent photothermal conversion capability, high drug loading capacity (260 µg mg(-1)), and magnetic resonance (MR) and photoacoustic (PA) imaging abilities...
March 2017: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://www.readbyqxmd.com/read/28330927/e3-ubiquitin-ligase-ubr5-drives-the-growth-and-metastasis-of-triple-negative-breast-cancer
#5
Liqiu Liao, Mei Song, Xin Li, Lili Tang, Tuo Zhang, Lixing Zhang, Yihang Pan, Lotfi Chouchane, Xiaojing Ma
Patients with triple negative breast cancers (TNBC) are at high risk for recurrence and metastasis at an early time despite standard treatment, underscoring the need for novel therapeutic modalities. Here we report for the first time a distinctive and profound role of the E3 ubiquitin ligase UBR5 in the growth and metastasis of TNBC. An analysis of primary TNBC specimen by whole exon sequencing revealed strong gene amplifications of UBR5 associated with the disease. UBR5 overexpression in TNBC tissues was confirmed at mRNA and protein levels...
March 22, 2017: Cancer Research
https://www.readbyqxmd.com/read/28324269/metformin-sensitizes-triple-negative-breast-cancer-to-proapoptotic-trail-receptor-agonists-by-suppressing-xiap-expression
#6
Elena Strekalova, Dmitry Malin, Harisha Rajanala, Vincent L Cryns
PURPOSE: Despite robust antitumor activity in diverse preclinical models, TNF-related apoptosis-inducing ligand (TRAIL) receptor agonists have not demonstrated efficacy in clinical trials, underscoring the need to identify agents that enhance their activity. We postulated that the metabolic stress induced by the diabetes drug metformin would sensitize breast cancer cells to TRAIL receptor agonists. METHODS: Human triple (estrogen receptor, progesterone receptor, and HER2)-negative breast cancer (TNBC) cell lines were treated with TRAIL receptor agonists (monoclonal antibodies or TRAIL peptide), metformin, or the combination...
March 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28319780/new-bis-hydroxymethyl-alkanoate-curcuminoid-derivatives-exhibit-activity-against-triple-negative-breast-cancer-in%C3%A2-vitro-and-in%C3%A2-vivo
#7
Min-Tsang Hsieh, Ling-Chu Chang, Hsin-Yi Hung, Hui-Yi Lin, Mei-Hui Shih, Chang-Hai Tsai, Sheng-Chu Kuo, Kuo-Hsiung Lee
Novel bis(hydroxymethyl) alkanoate curcuminoid derivatives were designed, synthesized and screened for in vitro antiproliferative and in vivo antitumor activity. Selected new compound 9a and curcumin were further evaluated for inhibitory activity against ER(+)/PR(+) breast cancer (MCF-7, T47D), HER 2(+) breast cancer (SKBR3, BT474, and MDA-MB-457) and triple negative breast cancer (TNBC) (HS-578T, MDA-MB-157, and MDA-MB-468) cell lines. In addition, compound 9a was evaluated in the MDA-MB-231 xenograft nude mice model...
March 8, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28314842/performance-of-mid-treatment-breast-ultrasound-and-axillary-ultrasound-in-predicting-response-to-neoadjuvant-chemotherapy-by-breast-cancer-subtype
#8
Rosalind P Candelaria, Roland L Bassett, William Fraser Symmans, Maheshwari Ramineni, Stacy L Moulder, Henry M Kuerer, Alastair M Thompson, Wei Tse Yang
BACKGROUND: The primary objective was to determine whether mid-treatment ultrasound measurements of index breast tumors and index axillary nodes of different cancer subtypes associate with residual cancer burden (RCB). METHODS: Patients with invasive breast cancer who underwent neoadjuvant chemotherapy and had pre-treatment and mid-treatment breast and axillary ultrasound were included in this single-institution, retrospective cohort study. Linear regression analysis assessed associations between RCB with (a) change in index breast tumor size, (b) change in index node size, and (c) absolute number of abnormal nodes at mid-treatment...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28314283/stable-shrna-silencing-of-lactate-dehydrogenase-a-ldha-in-human-mda-mb-231-breast-cancer-cells-fails-to-alter-lactic-acid-production-glycolytic-activity-atp-or-survival
#9
Nzinga Mack, Elizabeth A Mazzio, David Bauer, Hernan Flores-Rozas, Karam F A Soliman
BACKGROUND: In the US, African Americans have a high death rate from triple-negative breast cancer (TNBC), characterized by lack of hormone receptors (ER, PR, HER2/ERRB2) which are otherwise valuable targets of chemotherapy. There is a need to identify novel targets that negatively impact TNBC tumorigenesis. TNBCs release an abundance of lactic acid, under normoxic, hypoxic and hyperoxic conditions; this referred to as the Warburg effect. Accumulated lactic acid sustains peri-cellular acidity which propels metastatic invasion and malignant aggressive transformation...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28299476/a-comparison-of-the-molecular-subtypes-of-triple-negative-breast-cancer-among-non-asian-and-taiwanese-women
#10
Ling-Ming Tseng, Jen-Hwey Chiu, Chun-Yu Liu, Yi-Fang Tsai, Yun-Lin Wang, Chu-Wen Yang, Yi-Ming Shyr
BACKGROUND: "Precision medicine" is a concept that by utilizing modern molecular diagnostics, an effective therapy is accurately applied for each cancer patient to improve their survival rates. The treatment of triple-negative breast cancer (TNBC) remains a challenging issue. The aim of this study was to compare the molecular subtypes of triple-negative breast cancer (TNBC) between Taiwanese and Non-Asian women. METHODS: GEO Datasets for non-Asian (12 groups, n = 1450) and Taiwanese (3 groups, n = 465) breast cancer, including 617 TNBC, were acquired, normalized and cluster analyzed...
March 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28294120/down-regulation-of-adam33-as-a-predictive-biomarker-of-aggressive-breast-cancer
#11
Graciele C M Manica, Caroline F Ribeiro, Marco A S de Oliveira, Isabela T Pereira, Andressa Chequin, Edneia A S Ramos, Liliane M B Klassen, Ana Paula M Sebastião, Larissa M Alvarenga, Silvio M Zanata, Lucia De Noronha, Iris Rabinovich, Fabricio F Costa, Emanuel M Souza, Giseli Klassen
Breast cancer is a heterogeneous disease with differences in its clinical, molecular and biological features. Traditionally, immunohistochemical markers together with clinicopathologic parameters are used to classify breast cancer and to predict disease outcome. Triple-negative breast cancer (TNBC) is a particular type of breast cancer that is defined by a lack of expression of hormonal receptors and the HER2 gene. Most cases of TNBC also have a basal-like phenotype (BLBC) with expression of cytokeratin 5/6 and/or EGFR...
March 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28293912/breast-cancer-subtype-distribution-is-different-in-normal-weight-overweight-and-obese-women
#12
Victoria Gershuni, Yun R Li, Austin D Williams, Alycia So, Laura Steel, Elena Carrigan, Julia Tchou
PURPOSE: Obesity is associated with tumor promoting pathways related to insulin resistance and chronic low-grade inflammation which have been linked to various disease states, including cancer. Many studies have focused on the relationship between obesity and increased estrogen production, which contributes to the pathogenesis of estrogen receptor-positive breast cancers. The link between obesity and other breast cancer subtypes, such as triple-negative breast cancer (TNBC) and Her2/neu+ (Her2+) breast cancer, is less clear...
March 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28292011/jatamanvaltrate-p-induces-cell-cycle-arrest-apoptosis-and-autophagy-in-human-breast-cancer-cells-in-vitro-and-in-vivo
#13
Bo Yang, Rui Zhu, Shasha Tian, Yiqi Wang, Siyue Lou, Huajun Zhao
Jatamanvaltrate P is a novel iridoid ester isolated from Valeriana jatamansi Jones, a traditional medicine used to treat nervous disorders. In this study, we found that Jatamanvaltrate P possessed notable antitumor properties and therefore evaluated its anticancer effects against human breast cancer cells in vitro and in vivo. Jatamanvaltrate P inhibited the growth and proliferation of MCF-7 and triple-negative breast cancer (TNBC) cell lines (MDA-MB-231, MDA-MB-453 and MDA-MB-468) in a concentration-dependent manner, while displayed relatively low cytotoxicity to human breast epithelial cells (MCF-10A)...
March 10, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28291390/efficacy-and-safety-of-anti-trop-2-antibody-drug-conjugate-sacituzumab-govitecan-immu-132-in-heavily-pretreated-patients-with-metastatic-triple-negative-breast-cancer
#14
Aditya Bardia, Ingrid A Mayer, Jennifer R Diamond, Rebecca L Moroose, Steven J Isakoff, Alexander N Starodub, Nikita C Shah, Joyce O'Shaughnessy, Kevin Kalinsky, Michael Guarino, Vandana Abramson, Dejan Juric, Sara M Tolaney, Jordan Berlin, Wells A Messersmith, Allyson J Ocean, William A Wegener, Pius Maliakal, Robert M Sharkey, Serengulam V Govindan, David M Goldenberg, Linda T Vahdat
Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabolite of irinotecan. Patients and Methods We evaluated sacituzumab govitecan in a single-arm, multicenter trial in patients with relapsed/refractory metastatic TNBC who received a 10 mg/kg starting dose on days 1 and 8 of 21-day repeated cycles. The primary end points were safety and objective response rate; secondary end points were progression-free survival and overall survival...
March 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28290700/metabolic-response-to-everolimus-in-patient-derived-triple-negative-breast-cancer-xenografts
#15
Leslie R Euceda, Deborah K Hill, Endre Stokke, Rana Hatem, Rania El Botty, Ivan Bièche, Elisabetta Marangoni, Tone F Bathen, Siver A Moestue
Patients with triple negative breast cancer (TNBC) are unresponsive to endocrine and anti-HER2 pharmacotherapy, limiting their therapeutic options to chemotherapy. TNBC is frequently associated with abnormalities in the PI3K/AKT/mTOR signaling pathway; drugs targeting this pathway are currently being evaluated in these patients. However, response is variable, partly due to heterogeneity within TNBC, conferring a need to identify biomarkers predicting response and resistance to targeted therapy. In this study, we used a metabolomics approach to assess response to the mTOR inhibitor everolimus in a panel of TNBC patient-derived xenografts (PDX) (n=103 animals)...
March 14, 2017: Journal of Proteome Research
https://www.readbyqxmd.com/read/28286613/treatment-outcomes-and-clinicopathologic-characteristics-of-triple-negative-breast-cancer-a-report-from-cancer-institute-of-iran
#16
Mehrzad Mirzania, Seyed Reza Safaee, Farhad Shahi, Issa Jahanzad, Ghazal Zahedi, Reza Mehdizadeh
Background: Triple-negative breast cancers (TNBC) have a more aggressive course and are associated with poorer prognosis in comparison with other subtypes of breast cancer. One of the most common subtypes of TNBC is basal-like. The aim of this study was to investigate clinicopathological characteristics and clinical course of TNBC in Iranian women and compare them with other studies. Subjects and Methods: Between March 2009 and February 2011, patients with breast cancer in Cancer Institute of Iran were selected and then followed-up for 2 years...
January 1, 2017: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/28284864/development-of-a-novel-near-infrared-fluorescent-theranostic-combretastain-a-4-analogue-yk-5-252-to-target-triple-negative-breast-cancer
#17
Yali Kong, Jacqueline Smith, Kongwen Li, Jake Cui, John Han, Shujie Hou, Milton L Brown
The treatment of triple negative breast cancer (TNBC) is a significant challenge to cancer research. The lack of hormone receptors limits the treatment options available to patients with this diagnosis, forcing them to endure prolonged radiation and chemotherapy. Anti-angiogenesis is a chemotherapeutic strategy that targets the vasculature of tumors. Combretastatin A-4 (CA-4) is a well-known vasculature-disrupting agent, which has been shown to effectively kill a variety of cancers through inhibition of tubulin polymerization...
February 24, 2017: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/28281569/treating-triple-negative-breast-cancer-cells-with-erlotinib-plus-a-select-antioxidant-overcomes-drug-resistance-by-targeting-cancer-cell-heterogeneity
#18
Bin Bao, Cristina Mitrea, Priyanga Wijesinghe, Luca Marchetti, Emily Girsch, Rebecca L Farr, Julie L Boerner, Ramzi Mohammad, Greg Dyson, Stanley R Terlecky, Aliccia Bollig-Fischer
Among breast cancer patients, those diagnosed with the triple-negative breast cancer (TNBC) subtype have the worst prog-nosis. TNBC does not express estrogen receptor-alpha, progesterone receptor, or the HER2 oncogene; therefore, TNBC lacks targets for molecularly-guided therapies. The concept that EGFR oncogene inhibitor drugs could be used as targeted treatment against TNBC has been put forth based on estimates that 30-60% of TNBC express high levels of EGFR. However, results from clinical trials testing EGFR inhibitors, alone or in combination with cytotoxic chemotherapy, did not improve patient outcomes...
March 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28278077/anti-angiogenic-treatment-promotes-triple-negative-breast-cancer-invasion-via-vasculogenic-mimicry
#19
Huizhi Sun, Danfang Zhang, Zhi Yao, Xian Lin, Jiameng Liu, Qiang Gu, Xueyi Dong, Fang Liu, Yi Wang, Nan Yao, Siqi Cheng, Linqi Li, Shuya Sun
Agents that target angiogenesis have shown limited efficacy for human triple-negative breast cancer (TNBC) in clinical trials. Along with endothelium-dependent vessels, there is also vasculogenic mimicry (VM) in the microcirculation of malignant tumors. The role of VM is not completely understood regarding anti-angiogenic treatment. In this study, human TNBC MDA-MB-231 and Hs578T and non-TNBC MCF-7 and BT474 tumor-bearing mice were treated with sunitinib, an anti-angiogenic drug, using a clinically relevant schedule...
February 21, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28277293/prospective-comparison-of-outcome-after-treatment-for-triple-negative-and-non-triple-negative-breast-cancer
#20
D P Joyce, D Murphy, A J Lowery, C Curran, K Barry, C Malone, R McLaughlin, M J Kerin
INTRODUCTION: Triple-negative breast cancers (TNBC) are associated with a poor prognosis owing to an aggressive phenotype. We aimed to carry out a prospective study comparing management strategies and response to therapy in TNBC and non-TNBC patients. METHODS: Data were obtained from a prospectively maintained database of patients treated for breast cancer. RESULTS: A total of 142 TNBC and 142 age-, stage- and NPI-matched non-TNBC patients were treated...
October 27, 2016: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
keyword
keyword
23272
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"